# Albertsons Companies Inc. (ACI) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACI/thesis · /stocks/ACI/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ACI
step: 04
title: Financial Quality
created: 2026-05-27
---

### Step 04 — Financial Quality: Albertsons Companies, Inc. (ACI)

#### 1. Statement Quality Overview

ACI reports under U.S. GAAP as an SEC-registered public company. Auditor is Deloitte & Touche LLP (continuously since at least 2020). No material weaknesses, restatements, or going concern qualifications in the filing history reviewed [S1].

**Key quality observation:** The largest GAAP vs. adjusted gap in ACI's history arises in FY2026 from the $773.8M opioid settlement charge. This is a genuine non-recurring, litigation-settlement obligation (disclosed since 2021; settled April 2026). The adjusted earnings ($2.18 EPS vs. $0.40 GAAP EPS) strip this out, which is analytically defensible — but investors should note the $482M NPV after-tax cash impact spread over 9 years is a real cost, not a free pass [S2].

---

#### 2. Statement-Quality Adjustments

##### Income Statement Adjustments

| Item | FY2026 Impact | Direction | Justification |
|------|--------------|-----------|--------------|
| Opioid settlement charge | $773.8M pre-tax ($600M after-tax) | Subtract from reported earnings | Non-recurring litigation reserve; settlement announced April 2026 [S2] |
| Merger-related legal/advisory costs | ~$50–100M (estimate; Kroger deal) | Subtract | One-time deal costs during merger process |
| CEO transition retention bonuses | ~$10M (estimate) | Subtract | One-time management change cost |

**Reported FY2026 GAAP Net Income:** $217M ($0.40/share)
**Adjusted Net Income:** $1,209M ($2.18/share)
**Difference:** $992M — the vast majority attributable to opioid settlement

##### Balance Sheet Adjustments

| Item | Impact | Notes |
|------|--------|-------|
| Goodwill + intangibles | ~$3.3B+ (estimate) | Result of decades of grocery M&A; drives negative tangible book value |
| Operating lease right-of-use assets | Substantial | ACI leases most stores; operating leases ~$6–7B estimated |
| Finance lease liabilities | Included in LT debt ($8.9B incl. finance leases) | True economic debt burden |
| Opioid settlement liability | Now on balance sheet as reserve | ~$774M booked Q4 FY2026 |

**Tangible book value/share: -$2.78 (FY2026)** — negative due to accumulated goodwill from historic acquisitions (Safeway 2015, United Supermarkets, etc.). This is typical for asset-light-property grocery chains with M&A history and does not represent insolvency risk [S3].

##### Cash Flow Quality
- **Operating cash flow** ($2,367M FY2026) significantly exceeds GAAP net income ($217M) — as expected for a retailer with large D&A + lease adjustments
- **Free cash flow** ($527M) declined substantially from FY2025 ($749M); primary driver is opioid settlement accrual timing and elevated capex
- FCF quality: REASONABLE. ACI has consistently generated positive FCF despite heavy capex ($1.6–2.1B/year). Working capital dynamics (negative, supplier-paid model) are structural free cash sources
- **D&A:** Estimated ~$2.8B/year based on EBITDA gap vs. operating income; supports book-earnings quality (D&A is real economic cost of store infrastructure)

---

#### 3. Revenue Recognition Quality

ACI's revenue recognition is standard retail — point-of-sale. No complex multi-element arrangements or significant deferred revenue. Key considerations:
- **Gift cards:** Recognized upon redemption or expiration (breakage)
- **Loyalty rewards:** Accounted for as performance obligations; deferred portion reduces revenue at point of sale
- **Fuel revenue:** Recorded on gross basis (significant for margin analysis; fuel has very low margins)
- **Pharmacy:** Revenue = drug cost + dispensing fee; prior authorization, DIR fees, and rebates create complexity but are standard pharmacy industry practice

**Assessment: Revenue recognition is straightforward and consistent with retail industry norms. No red flags.**

---

#### 4. Adversarial Research Sweep

*Per the full-research-gpt Step 04 spec, this section covers short reports, investigations, lawsuits, regulatory actions, and adversarial claims against ACI. Transcript analysis not performed (coverage-next-full path); sourced from press releases, SEC filings, and web research.*

##### 4.1 Opioid Litigation [MATERIAL — RESOLVED]
- **Claim:** ACI pharmacies improperly dispensed opioid prescriptions, contributing to the U.S. opioid epidemic
- **Status:** SETTLED — National settlement framework announced April 14, 2026: $773.8M over 9 years, covering nearly all state, local, and tribal government claims [S2]
- **Financial impact:** $773.8M pre-tax charge in Q4 FY2026; $482M estimated after-tax NPV; first payment April 30, 2026
- **Risk residual:** Some individual plaintiff claims may not be covered by the national framework; ongoing monitoring required
- **Assessment:** The largest known legal risk is now quantified and provisioned. Settlement is not an admission of liability.

##### 4.2 FTC Pricing Investigations
- **Claim:** In 2026, FTC/DOJ have been investigating grocery pricing practices industry-wide, including ACI
- **Status:** No enforcement action against ACI disclosed as of May 2026
- **Financial impact:** Unknown; not provisioned
- **Assessment:** Industry-wide regulatory risk. Material if enforcement leads to consent decree or fines, but not imminent [S4]

##### 4.3 Labor / Union Disputes
- **Claim:** Colorado labor strike (late 2025) — UFCW vs. ACI stores in Colorado
- **Status:** Resolved; strike ended in late 2025 per available information
- **Financial impact:** Modest revenue disruption during strike period; higher labor costs in settlement
- **Assessment:** Recurring risk — ACI renegotiates ~50–75 union contracts per year across 230,000+ unionized employees. Any single strike is manageable; pattern of escalating labor costs is a long-run margin headwind [S5]

##### 4.4 Kroger Merger Lawsuit
- **Claim:** ACI sued Kroger for $600M+ termination fee plus damages following Dec 2024 merger termination
- **Status:** Pending litigation
- **Counter-risk:** Kroger claims ACI's demands are "baseless"
- **Financial impact:** If ACI wins: $600M+ cash inflow (material positive). If ACI loses: no incremental cost (already incurred deal costs separately)
- **Assessment:** Binary upside optionality. Timeline uncertain (likely 12–24 months to resolution). Not in base case valuation [S6]

##### 4.5 Short-Seller / Bear Case Reports
- No prominent short reports specifically targeting ACI's accounting were found in research
- Primary bearish thesis is competitive/strategic (Aldi threat, margin compression) rather than accounting fraud
- **Assessment:** No material accounting fraud risk identified. ACI's financials are a legitimate business with thin margins, not a fabrication.

##### 4.6 Historical Accounting / Restatement
- No material restatements in ACI's SEC filing history (going back to 2017 when company began filing as Albertsons Companies, Inc. following predecessor reorganizations)
- **Assessment: Clean**

---

#### 5. Leverage & Interest Coverage Quality

| Metric | FY2026 | FY2025 | Assessment |
|--------|--------|--------|------------|
| Adj. EBITDA | $3,902M | $4,045M | — |
| Interest Expense (est.) | ~$600M | ~$500M | — |
| Interest Coverage (adj. EBITDA/Int.) | ~6.5x | ~8x | ADEQUATE |
| Net Debt / Adj. EBITDA | 2.24x | 2.24x | MANAGEABLE |
| Fixed Charge Coverage | — | — | Not directly available |

Interest coverage of ~6.5x is acceptable for investment-grade-adjacent corporate credit. ACI's debt is rated Ba1/BB+ (near investment grade) [S7]. The January 2026 refinancing eliminated 2027/2028 maturities, pushing next major maturities to 2031/2032/2034 — materially reducing near-term refinancing risk.

---

#### 6. Financial Quality Score

| Category | Score (1-5) | Notes |
|----------|------------|-------|
| Revenue recognition | 5 | Simple POS retail; no complex arrangements |
| Earnings quality (adj. vs. GAAP) | 3 | Large opioid gap is real cash cost; adjusted basis defensible |
| Cash flow generation | 4 | OCF >> net income; consistent FCF positive |
| Balance sheet transparency | 4 | Large lease obligations; disclosed clearly |
| Leverage management | 4 | 2.2x net debt/EBITDA; refinanced near-term maturities |
| Legal/regulatory clean bill | 3 | Opioid settled; pricing investigation + labor risk ongoing |
| **Overall** | **3.8 / 5** | **Adequate quality for investment-grade equivalent operation** |

---

#### Source Index

| ID | Source | Reference |
|----|--------|-----------|
| S1 | SEC EDGAR submissions (Deloitte auditor) | https://data.sec.gov/submissions/CIK0001646972.json |
| S2 | ACI Opioid Settlement Press Release (Apr 2026) | https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2026/Albertsons-Companies-Announces-National-Opioid-Settlement-Framework/default.aspx |
| S3 | StockAnalysis.com Balance Sheet | https://stockanalysis.com/stocks/aci/financials/balance-sheet/ |
| S4 | Sahm Capital — ACI Pricing/Opioid Analysis (May 2026) | https://www.sahmcapital.com/news/content/should-opioid-settlement-and-pricing-lawsuit-pressures-require-action-from-albertsons-companies-aci-investors-2026-05-02 |
| S5 | Progressive Grocer — CEO Commentary | https://progressivegrocer.com/albertsons-ceo-looks-toward-year-ahead |
| S6 | Harvard Law / WISTV — Kroger Termination | https://corpgov.law.harvard.edu/2025/01/21/practice-points-arising-from-albertsons-claims-against-kroger-for-breach-of-their-merger-agreement/ |
| S7 | TipRanks — ACI Debt Refinancing | https://www.tipranks.com/news/company-announcements/albertsons-companies-issues-new-senior-notes-to-refinance-debt |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACI/fundamental

## Navigation

- Overview: /stocks/ACI
- Financials (this page): /stocks/ACI/financials
- Thesis: /stocks/ACI/thesis
- Investment Memo: /stocks/ACI/memo
- Coverage universe: /stocks